Watertown, Mass. — August 11, 2025 — Leads & Copy — Kymera Therapeutics, Inc. (NASDAQ: KYMR) announced positive data from its KT-621 (STAT6) Phase 1 healthy volunteer trial, surpassing its target product profile. The company also reported financial results for the second quarter ended June 30, 2025, and provided business highlights and pipeline updates.
The KT-621 BroADen Phase 1b trial in atopic dermatitis (AD) patients is on track to report data in Q4 2025. Doses have been selected for KT-621 Phase 2b trials in AD and asthma, expected to begin in Q4 2025 and Q1 2026, respectively. KT-579 (IRF5) IND-enabling studies are ongoing, with a Phase 1 clinical trial anticipated in early 2026. Kymera entered a strategic partnership with Gilead to develop CDK2 degraders, potentially totaling $750 million in payments. As of July 31, 2025, the company is well-capitalized with $1 billion in cash, extending its runway into the second half of 2028.
According to Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics, the first half of the year has been rich in data and milestones that build upon our scientific achievements and further validate the potential impact of our industry leading oral immunology pipeline.
Kymera will hold a video conference call and webcast today at 8:30 a.m. ET.
Contact: Justine Koenigsberg, Vice President, Investor Relations, investors@kymeratx.com, media@kymeratx.com, 857-285-5300
Source: Kymera Therapeutics, Inc.
